Combined Bezafibrate and Medroxyprogesterone Acetate: Potential Novel Therapy for Acute Myeloid Leukaemia - Bertin Instruments

    Scientific publications

    Combined Bezafibrate and Medroxyprogesterone Acetate: Potential Novel Therapy for Acute Myeloid Leukaemia

    Farhat L. Khanim1, Rachel E. Hayden1, Jane Birtwistle1, Alessia Lodi2, Stefano Tiziani2, Nicholas J.Davies1, Jon P. Ride1, Mark R. Viant1, Ulrich L. Gunther2, Joanne C. Mountford3, Heinrich Schrewe4,5,Richard M. Green1, Jim A. Murray6, Mark T. Drayson7., Chris M. Bunce1.*
    Sources: 1 School of Biosciences, University of Birmingham, Birmingham, United Kingdom, 2 Henry Wellcome Building for Biomolecular NMR Spectroscopy, CRUK Institute for Cancer Studies, University of Birmingham, Birmingham, United Kingdom, 3 Division of Cancer Sciences and Molecular Pathology, University of Glasgow, Glasgow, United Kingdom, 4 Department of Developmental Genetics, Max-Planck Institute for Molecular Genetics, Berlin, Germany, 5 Institute of Medical Genetics, Charite´-University Medicine Berlin, Berlin, Germany, 6 Centre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham, United Kingdom, 7 Division of Immunity and Infection, University of Birmingham, Birmingham, United Kingdom
    Khanim FL, Hayden RE, Birtwistle J, Lodi A, Tiziani S, et al. (2009) Combined Bezafibrate and Medroxyprogesterone Acetate: Potential Novel Therapy forAcute Myeloid Leukaemia. PLoS ONE 4(12): e8147. doi:10.1371/journal.pone.0008147

    Sample name

    Cells lines

    ANY QUESTIONS? CONTACT AN EXPERT

    Please fill in this form if you wish to contact our sales team or receive further information.

    My Account
    Forgot password ?

    Add a question !

    Add a question